In-depth profiling of tumor tissue derived from malignant pleural mesothelioma patients identifies potential biomarkers predicting response to immune-checkpoint inhibitor therapy

Dmitrii Shek; Bo Gao; Hema Mahajan; Adnan Nagrial; Matteo S Carlino; Fabio Luciani; Scott A Read; Golo Ahlenstiel

doi:10.1016/j.gendis.2023.101189

In-depth profiling of tumor tissue derived from malignant pleural mesothelioma patients identifies potential biomarkers predicting response to immune-checkpoint inhibitor therapy

Genes Dis. 2023 Dec 3;11(6):101189. doi: 10.1016/j.gendis.2023.101189. eCollection 2024 Nov.

Authors

Dmitrii Shek^{1

2

3}, Bo Gao^{3

4

5}, Hema Mahajan^{4

5

6}, Adnan Nagrial^{3

4

5}, Matteo S Carlino^{3

4

5

7}, Fabio Luciani^{8

9}, Scott A Read^{1

2

3}, Golo Ahlenstiel^{1

2

3}

Affiliations

¹ Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia.
² Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
³ Blacktown Mt Druitt Hospital, Sydney, NSW 2148, Australia.
⁴ Westmead Hospital, Sydney, NSW 2145, Australia.
⁵ Westmead Clinical School, University of Sydney, Sydney, NSW 2145, Australia.
⁶ Institute of Clinical Pathology and Medical Research, Sydney, NSW 2145, Australia.
⁷ Melanoma Institute Australia, Sydney, NSW 2065, Australia.
⁸ School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
⁹ Garvan Institute for Medical Research, Sydney, NSW 2010, Australia.

No abstract available